S. L. Andis

发表

SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide.

D. Schoepp, D. Barda, Michael P Johnson, 2004, Bioorganic & medicinal chemistry letters.

Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.

L. Hertel, R. Schultz, R. Merriman, 1993, Oncology research.

Effect of albumin on antitumor activity of diarylsulfonylureas.

R. Schultz, G. Grindey, S. L. Andis, 1993, Anticancer research.

Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.

R. Schultz, C. Shih, J. Tonkinson, 1998, British Journal of Cancer.

Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist.

M. Bures, D. Schoepp, C. Domínguez, 2005, Journal of medicinal chemistry.

Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.

G. Stephenson, M. Bures, D. Schoepp, 2007, Journal of medicinal chemistry.

Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.

R. Schultz, C. Shih, R. Moran, 1995, Molecular pharmacology.

Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.

J. Grutsch, D. Schoepp, J. Wepsiec, 1999, Journal of medicinal chemistry.

Total Synthesis of Seco (+)- and ent-(−)-Oxaduocarmycin SA: Construction of the (Chloromethyl)indoline Alkylating Subunit by a Novel Intramolecular Aryl Radical Cyclization onto a Vinyl Chloride

F. Mohamadi, R. Schultz, M. M. Spees, 1997 .

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

R M Schultz, S. B. Gates, R. Schultz, 1997, Cancer research.

C3'-cis-Substituted carboxycyclopropyl glycines as metabotropic glutamate 2/3 receptor agonists: synthesis and SAR studies.

D. Schoepp, C. Pedregal, J. Pérez-Castells, 2005, Bioorganic & medicinal chemistry.

Synthesis and biological evaluation of cryptophycin analogs with substitution at C-6 (fragment C region).

M. Martinelli, R. Schultz, C. Shih, 1999, Bioorganic & medicinal chemistry letters.

Total Synthesis of Cryptophycin Analogues. Isosteric Replacement of the C−D Ester

R. Schultz, B. Norman, T. Hemscheidt, 1998 .

A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.

R. Schultz, C. Shih, L. L. Habeck, 1994, Cancer research.

Synthesis and biological evaluation of a new series of dihydrofolate reductase inhibitors based on the 4-(2,6-diamino-5-pyrimidinyl)alkyl-L-glutamic acid structure

S. B. Gates, R. Schultz, C. Shih, 1996 .

The synthesis and biological activity of a series of 2,4-diaminopyrido[2,3-d]pyrimidine based antifolates as antineoplastic and antiarthritic agents.

S. B. Gates, R. Schultz, C. Shih, 1999, Bioorganic & medicinal chemistry letters.

Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis

R. Schultz, C. Shih, J. Tonkinson, 1997, Cancer Chemotherapy and Pharmacology.

A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.

R. Schultz, R. Al-awar, T. Corbett, 2003, Journal of medicinal chemistry.

Medicinal chemistry of difluoropurines.

L. Hertel, G. Grindey, S. L. Andis, 1995, Seminars in oncology.

In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.

G. Powis, R. Schultz, A. Gallegos, 1995, Anticancer research.

An assessment of the antithymine and antipurine characteristics of MTA (LY231514) in CCRF-CEM cells.

R. Schultz, C. Shih, J. Tonkinson, 2000, Advances in enzyme regulation.

Novel cryptophycin antitumor agents: synthesis and cytotoxicity of fragment "B" analogues.

R. Schultz, V. Patel, S. L. Andis, 1999, Journal of medicinal chemistry.

Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.

R. Schultz, C. Shih, J. Tonkinson, 1999, Seminars in oncology.